1-叔丁氧羰基-3-胺基环丁胺 | 193269-78-2

• 物质功能分类: 化学试剂 - 有机试剂 - 肟
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 中文名称: 1-叔丁氧羰基-3-胺基环丁胺
• 中文别名: 1-Boc-3-氨基氮杂环丁烷；1-Boc-3-氨基吖丁啶；3-氨基-1-N-BOC-氮杂环丁烷；1-叔丁氧羰基-3-氨基杂氮环丁烷；1-叔丁氧羰基-3-氨基氮杂环丁烷；1-boc-3-氨基氮杂环丁烷；1-B0C-3-氨基氮杂环丁烷；1-叔丁氧羰基-3-胺基吖丁啶；3-氨基-1-N-Boc-氮杂环丁烷；N-BOC-3-氨基氮杂环丁烷
• 英文名称: 3-aminoazetidine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 3-aminoazetidine-1-carboxylate；1-Boc-3-aminoazetidine；3-amino-1-N-Boc-azetidine；1-tert-butoxycarbonyl-3-aminoazetidine；1-tert-butoxycarbonyl-3-aminocyclobutylamine；tert-butyl 3-amino-1-azetidinecarboxylate；1-N-Boc-3-aminoazetidine；3-amino-1-Boc-azetidine；1-Boc-3-(amino)azetidine
• CAS: 193269-78-2
• 化学式: C₈H₁₆N₂O₂
• mdl: MFCD01861753
• 分子量: 172.227
• InChiKey: WPGLRFGDZJSQGI-UHFFFAOYSA-N

物化性质

• 沸点：
  79-81 3mm
• 密度：
  1.1g/ml
• 溶解度：
  可溶于二甲基亚砜、甲醇、水
• 稳定性/保质期：
  避免与氧化物、空气、二氧化碳和酸接触。

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  8
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R34
• 海关编码：
  2933990090
• 危险品运输编号：
  2735
• 包装等级：
  Ⅲ
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P501,P264,P280,P303+P361+P353,P301+P330+P331,P363,P304+P340+P310,P305+P351+P338+P310,P405
• 危险性描述：
  H314
• 储存条件：
  保存方法：在密闭、阴凉、通风干燥的地方存放。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-BOC-3-Aminoazetidine
Synonyms: tert-Butyl 3-aminoazetidine-1-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H314: Causes severe skin burns and eye damage
H318: Causes serious eye damage
P273: Avoid release to the environment
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-BOC-3-Aminoazetidine
CAS number: 193269-78-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H16N2O2
Molecular weight: 172.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (1-BOC-3-Aminoazetidine)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

氮杂环丁烷类化合物因其作为医药中间体被大量使用而受到重视。近年来，通过各种官能团修饰成功制备并试验了许多新化合物，其中许多具有良好的药物活性。例如，1-二苯甲基-3-氨基氮杂环丁烷和1-二苯甲基-3-羟基-3-氨甲基氮杂环丁烷已被应用于抗菌性和抗抑郁类药物的合成。而1-叔丁氧羰基-3-胺基环丁胺也是重要的药物中间体，用于IRAK-4类抑制剂的合成。

反应信息

• 作为反应物：
  描述：

  1-叔丁氧羰基-3-胺基环丁胺 在 盐酸 、 sodium tetrahydroborate 、 三乙酰氧基硼氢化钠 、 sodium hydroxide 、 sodium t-butanolate 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 异丙醇 、 甲苯 为溶剂， 反应 122.25h， 生成 (2S)-2-[[(3β,15α,16α,23R,24S)-16,23-epoxy-24-ethoxy-15,25-dihydroxy-9,19-cyclolanostan-3-yl]oxy]-4-(1-isopropylazetidin-3-yl)morpholine
  参考文献：
  名称：

  公斤级三萜类萜烯衍生的γ-秘密酶调节剂的有效千克级合成的优化。

  摘要：

  这项工作描述了从植物固醇衍生的起始原料公斤级合成γ-分泌酶调节剂的演示。开发能够递送一公斤目标化合物的合成路线的关键是开发四反应望远镜工艺和三醇中间体的选择性O-烷基化。这些改进使得能够成功交付千克级的API，用于临床前开发研究。

  DOI：

  10.1021/op500072b
• 作为产物：
  描述：

  1-Boc-3-碘氮杂环丁烷 在 甲胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 1-叔丁氧羰基-3-胺基环丁胺
  参考文献：
  名称：

  Procollagen C-proteinase inhibitors

  摘要：

  它们及其盐、溶剂合物、前药等，其中取代基具有此处提及的值，是Procollagen C-蛋白酶（PCP）抑制剂，并在由PCP介导的疾病中具有用途。

  公开号：

  US20010021718A1
• 作为试剂：
  描述：

  1-叔丁氧羰基-3-胺基环丁胺 、 间三氟甲基马尿酸 在 1-叔丁氧羰基-3-胺基环丁胺 作用下， 以94的产率得到3-[2-(3-trifluoro-methyl-benzoylamino)-acetylamino]-azetidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2

  摘要：

  本发明涉及公式(I)的化合物。其中：R1、R2、R3和R4如规范中所定义。本发明还涉及包含公式(I)化合物的药物组合物，并通过给予公式(I)化合物的方法来预防、治疗或改善CCr2介导的综合症、疾病或疾病，例如II型糖尿病、肥胖症或哮喘。

  公开号：

  US20100144695A1

文献信息

• HETEROBICYCLIC COMPOUNDS
  申请人：Amgen Inc.

  公开号：US20130225552A1

  公开（公告）日：2013-08-29

  Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.

  Formula (I)的杂环化合物： 或其药用可接受的盐、互变异构体或立体异构体，如规范中所定义，并含有它们的组合物，以及制备这种化合物的方法。本文还提供了通过抑制PDE10来治疗由此可治疗的疾病或疾病的方法，如肥胖症、非胰岛素依赖型糖尿病、精神分裂症、躁郁症、强迫症、亨廷顿病等。
• IRAK DEGRADERS AND USES THEREOF
  申请人：Kymera Therapeutics, Inc.

  公开号：US20190192668A1

  公开（公告）日：2019-06-27

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• [EN] TARGETING COMPOUNDS<br/>[FR] COMPOSÉS DE CIBLAGE
  申请人：ZAFGEN INC

  公开号：WO2019118612A1

  公开（公告）日：2019-06-20

  The disclosure provides, at least in part, liver, intestine and/or kidney-targeting compounds and their use in treating liver, intestine and/or kidney disorders, such as non-alcoholic steatohepatitis, alcoholic steatohepatitis, hepatocellular carcinoma, liver cirrhosis, and hepatitis B; and/or chronic kidney disease, glomerular disease such as IGA nephropathy, lupus nephritis, or polycystic kidney disease. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

  该披露提供了至少部分针对肝脏、肠道和/或肾脏的化合物，以及它们在治疗肝脏、肠道和/或肾脏疾病中的用途，如非酒精性脂肪肝、酒精性脂肪肝、肝细胞癌、肝硬化和乙型肝炎；和/或慢性肾脏疾病、肾小球疾病，如IgA肾病、狼疮性肾炎或多囊肾病。这些化合物被认为对甲硫氨酰氨肽酶2具有活性。
• METALLO-BETA-LACTAMASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20160333021A1

  公开（公告）日：2016-11-17

  The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

  本发明涉及式(I)的化合物，这些化合物是金属β-内酰胺酶抑制剂，以及这些化合物的合成和与β-内酰胺类抗生素一起用于克服耐药性的用途。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF
  申请人：FUJIFILM Corporation

  公开号：US20150322063A1

  公开（公告）日：2015-11-12

  A compound represented by Formula [1] (in the formula, Z 1 represents N, CH, or the like; X 1 represents NH or the like; R 1 represents a heteroaryl group or the like; each of R 2 , R 3 , and R 4 represents a hydrogen atom, a halogen atom, an alkoxy group, or the like; and R 5 represents a heteroaryl group or the like) or salt thereof.

  由式[1]表示的化合物（在该式中，Z表示N、CH或类似物；X表示NH或类似物；R表示杂环烷基或类似物；R2、R3和R4中的每一个表示氢原子、卤原子、烷氧基或类似物；R5表示杂环烷基或类似物）或其盐。